• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by DA32 Life Science Tech Acquisition Corp. (Amendment)

    2/6/23 10:22:59 AM ET
    $DALS
    Blank Checks
    Finance
    Get the next $DALS alert in real time by email
    SC 13G/A 1 da32lifescience13ga1_123122.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    ( Amendment No.1 )*

    DA32 Life Science Tech

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    23312M106

    (CUSIP Number) 

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    x  Rule 13d-1(b)
    ¨  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

             
    CUSIP No. 23312M106   13G   Page 2 of 4 Pages
             

     

             
    1.  

    NAMES OF REPORTING PERSONS

     

    Victory Capital Management Inc.


    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    13-2700161

       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    New York
       

     

             
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.  

    SOLE VOTING POWER
     
    0

      6.   SHARED VOTING POWER
     
    0
      7.   SOLE DISPOSITIVE POWER
     
    0
      8.   SHARED DISPOSITIVE POWER
     
    0

     

             
    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    IA
       
             
             
                     
     
     

     

             
    CUSIP No. 23312M106   13G   Page 3 of 4 Pages
             

    Item 1.

      (a) Name of Issuer
    DA32 Life Science Tech
         
      (b)

    Address of Issuer’s Principal Executive Offices

    345 Park Ave. South 12th

    New York, Ny 10010

         

    Item 2.

      (a) Name of Persons Filing
    Victory Capital Management Inc.
         
      (b)

    Address of the Principal Office or, if none, residence
    4900 Tiedeman Rd. 4th Floor

    Brooklyn, OH 44144

         
      (c) Citizenship
    New York
         
      (d) Title of Class of Securities
    Common Stock
         
      (e) CUSIP Number
    23312M106
         

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           

    Item 4.  Ownership.

     
     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

             
      (a)   Amount beneficially owned:  0
             
      (b)   Percent of class:  0%
             
      (c)   Number of shares as to which the person has:
             
          (i)

    Sole power to vote or to direct the vote:  0

             
          (ii) Shared power to vote or to direct the vote:  0
             
          (iii) Sole power to dispose or to direct the disposition of:  0
             
          (iv)

    Shared power to dispose or to direct the disposition of:  0

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

             

    Item 5.  Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ¨

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

    The clients of Victory Capital Management Inc., including investment companies registered under the Investment Company Act of 1940 and separately managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the class of securities reported herein. No client has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of such class.

     

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     Not applicable

    Item 8.  Identification and Classification of Members of the Group.

     Not applicable.

    Item 9.  Notice of Dissolution of Group.

     Not applicable.

    Item 10.  Certification.

           
      (a)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
             
          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.  
             
             
     
     

     

             
    CUSIP No. 23312M106   13G   Page 4 of 4 Pages
             

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    2/6/2023

    Date

     

    /s/ Barry Garrett

    Signature

     

    Barry Garrett/ Chief Compliance Officer

    Name/Title

     

     

    Get the next $DALS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DALS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DALS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Crandell Keith disposed of 1,600,000 shares

    4 - DA32 Life Science Tech Acquisition Corp. (0001863294) (Issuer)

    8/10/23 8:28:16 PM ET
    $DALS
    Blank Checks
    Finance

    SEC Form 4: Arch Venture Fund Xi, L.P. disposed of 1,600,000 shares

    4 - DA32 Life Science Tech Acquisition Corp. (0001863294) (Issuer)

    8/10/23 8:27:17 PM ET
    $DALS
    Blank Checks
    Finance

    SEC Form 4: Deerfield Management Company, L.P. (Series C) disposed of 1,600,000 shares

    4 - DA32 Life Science Tech Acquisition Corp. (0001863294) (Issuer)

    8/1/23 5:24:40 PM ET
    $DALS
    Blank Checks
    Finance

    $DALS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DA32 Life Science Tech Acquisition Corp. Announces Redemption of Shares

    DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS) today announced that its board of directors (the "Board") has determined to redeem all of its outstanding shares of Class A common stock (the "Public Shares"), effective as of July 28, 2023, because the Company will not consummate an initial business combination within the time period required by its amended and restated certificate of incorporation. As of the close of business on July 28, 2023, the Public Shares will be deemed cancelled and will represent only the rights to receive the per-share redemption price of approximately $10.31 (after taking into account the removal of a portion of the accrued interest in the trust account to

    7/21/23 4:05:00 PM ET
    $DALS
    Blank Checks
    Finance

    $DALS
    SEC Filings

    View All

    SEC Form 15-12G filed by DA32 Life Science Tech Acquisition Corp.

    15-12G - DA32 Life Science Tech Acquisition Corp. (0001863294) (Filer)

    8/7/23 5:56:49 PM ET
    $DALS
    Blank Checks
    Finance

    SEC Form 25-NSE filed by DA32 Life Science Tech Acquisition Corp.

    25-NSE - DA32 Life Science Tech Acquisition Corp. (0001863294) (Subject)

    7/28/23 4:03:35 PM ET
    $DALS
    Blank Checks
    Finance

    DA32 Life Science Tech Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - DA32 Life Science Tech Acquisition Corp. (0001863294) (Filer)

    7/21/23 4:19:54 PM ET
    $DALS
    Blank Checks
    Finance

    $DALS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DA32 Life Science Tech Acquisition Corp. (Amendment)

    SC 13G/A - DA32 Life Science Tech Acquisition Corp. (0001863294) (Subject)

    2/7/24 1:45:26 PM ET
    $DALS
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by DA32 Life Science Tech Acquisition Corp. (Amendment)

    SC 13G/A - DA32 Life Science Tech Acquisition Corp. (0001863294) (Subject)

    9/11/23 4:36:54 PM ET
    $DALS
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by DA32 Life Science Tech Acquisition Corp. (Amendment)

    SC 13G/A - DA32 Life Science Tech Acquisition Corp. (0001863294) (Subject)

    8/8/23 10:29:56 AM ET
    $DALS
    Blank Checks
    Finance